New MS drug enters final testing phase to control disease activity
NCT ID NCT07321093
Summary
This study is testing whether a new drug called BCD-281 works as well as an existing reference drug for people with relapsing-remitting multiple sclerosis (RRMS). About 292 participants will be randomly assigned to receive either BCD-281 or the reference drug for 72 weeks, followed by an open-label period. The main goal is to see if BCD-281 reduces the number of active brain lesions and relapse rates compared to the standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LLC "Medis"
RECRUITINGNizhny Novgorod, Russia
Contact
Conditions
Explore the condition pages connected to this study.